Current Perspectives on the Systemic Management of Atopic Dermatitis

References

• Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251–8.e23. doi:10.1016/j.jaci.2009.10.009
   PubMed Web of Science ®Google Scholar
• Garg N, Silverberg JI. Epidemiology of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):281–288. doi:10.1016/j.clindermatol.2014.12.004
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–1138. doi:10.1016/j.jaci.2013.08.031
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289. doi:10.1016/j.det.2017.02.002
   PubMed Web of Science ®Google Scholar
• Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55(3):490–500. doi:10.1016/j.jaad.2006.05.048
   PubMed Web of Science ®Google Scholar
• CPI Inflation Calculator. U.S. Bureau of labor statistics. Available from: https://www.bls.gov/data/inflation_calculator.htm. Accessed February 12, 2021.
   Google Scholar
• Launois R, Ezzedine K, Cabout E, et al. Importance of out-of-pocket costs for adult patients with atopic dermatitis in France. J Eur Acad Dermatol Venereol. 2019;33(10):1921–1927. doi:10.1111/jdv.15581
   PubMed Web of Science ®Google Scholar
• Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis. 2019;104(3):174–177.
   PubMed Web of Science ®Google Scholar
• Hanifin J, Rajka G. Diagnostic features of atopic-dermatitis. Acta Derm Venereol. 1980;92:44–47.
   Google Scholar
• Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party’s Diagnostic Criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131(3):383–396. doi:10.1111/j.1365-2133.1994.tb08530.x
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Chopra R, Silverberg JI. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials. Am J Clin Dermatol. 2018;19(1):15–22. doi:10.1007/s40257-017-0299-4
   Web of Science ®Google Scholar
• Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390–401. doi:10.1016/j.jaad.2018.09.035
   PubMed Web of Science ®Google Scholar
• Schmitt J, Langan S, Deckert S, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132(6):1337–1347. doi:10.1016/j.jaci.2013.07.008
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Cella D, Silverberg JI. Patient-reported outcomes and quality of life measures in atopic dermatitis. Clin Dermatol. 2018;36(5):616–630. doi:10.1016/j.clindermatol.2018.05.011
   PubMed Web of Science ®Google Scholar
• Davari DR, Nieman EL, McShane DB, Morrell DS. Current perspectives on the management of infantile atopic dermatitis. J Asthma Allergy. 2020;13:563–573. doi:10.2147/jaa.S246175
   Web of Science ®Google Scholar
• Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6Suppl):S118–27. doi:10.1016/j.jaci.2003.09.033
   Google Scholar
• Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137. doi:10.1016/j.anai.2017.10.037
   PubMed Web of Science ®Google Scholar
• Tackett KJ, Jenkins F, Morrell DS, McShane DB, Burkhart CN. Structural racism and its influence on the severity of atopic dermatitis in African American children. Pediatr Dermatol. 2020;37(1):142–146. doi:10.1111/pde.14058
   PubMed Web of Science ®Google Scholar
• Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836–845. doi:10.1111/all.12619
   PubMed Web of Science ®Google Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi:10.1016/s0140-6736(20)31286-1
   PubMed Web of Science ®Google Scholar
• Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. doi:10.1038/ng1767
   PubMed Web of Science ®Google Scholar
• Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi:10.1111/bjd.16934
   PubMed Web of Science ®Google Scholar
• Powers CE, McShane DB, Gilligan PH, Burkhart CN, Morrell DS. Microbiome and pediatric atopic dermatitis. J Dermatol. 2015;42(12):1137–1142. doi:10.1111/1346-8138.13072
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–633. doi:10.1016/j.jaad.2017.06.042
   PubMed Web of Science ®Google Scholar
• Dupixent® (Dupilumab) Injection [Prescribing Information]. Tarrytown: Regeneron Pharmaceuticals, Inc; 2020.
   Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi:10.1016/j.jaad.2014.03.030
   PubMed Web of Science ®Google Scholar
• Seger EW, Wechter T, Strowd L, Feldman SR. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol. 2019;80(2):411–416.e4. doi:10.1016/j.jaad.2018.09.053
   PubMed Web of Science ®Google Scholar
• Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659–667. doi:10.1001/jamadermatol.2020.0796
   PubMed Web of Science ®Google Scholar
• Vermeulen FM, Gerbens LAA, Schmitt J, et al. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema. Br J Dermatol. 2020;183(6):1073–1082. doi:10.1111/bjd.18959
   PubMed Web of Science ®Google Scholar
• Totri CR, Eichenfield LF, Logan K, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol. 2017;76(2):281–285. doi:10.1016/j.jaad.2016.09.021
   PubMed Web of Science ®Google Scholar
• Sekhon S, Bhutani T, Koo JYM. 17 - Cyclosporine. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy (Fourth Edition). Elsevier; 2021:187–198.e3.
   Google Scholar
• Neoral® (Cyclosporine) Capsules [Prescribing Information]. East Hanover: Novartis Pharmaceuticals Corporation; 2009.
   Google Scholar
• Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338(8760):137–140. doi:10.1016/0140-6736(91)90134-b
   PubMed Web of Science ®Google Scholar
• van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol. 1994;130(5):634–640. doi:10.1111/j.1365-2133.1994.tb13111.x
   PubMed Web of Science ®Google Scholar
• Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol. 1995;132(1):106–112. doi:10.1111/j.1365-2133.1995.tb08633.x
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol. 1996;34(6):1016–1021. doi:10.1016/s0190-9622(96)90281-9
   PubMed Web of Science ®Google Scholar
• Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142(1):52–58. doi:10.1046/j.1365-2133.2000.03241.x
   PubMed Web of Science ®Google Scholar
• Garrido Colmenero C, Blasco Morente G, Tercedor Sánchez J. Oral cyclosporine weekend therapy: a new maintenance therapeutic option in patients with severe atopic dermatitis. Pediatr Dermatol. 2015;32(4):551–552. doi:10.1111/pde.12592
   PubMed Web of Science ®Google Scholar
• Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606–619. doi:10.1111/j.1468-3083.2006.02023.x
   PubMed Web of Science ®Google Scholar
• Grove D, Rahnama-Moghadam S. 15 - Azathioprine. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy (Fourth Edition). Elsevier; 2021:169–177.e3.
   Google Scholar
• Imuran® (Azathioprine) Tablets 50mg [Prescribing Information]. San Diego: Prometheus Laboratories Inc; 2011.
   Google Scholar
• Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147(2):324–330. doi:10.1046/j.1365-2133.2002.04989.x
   PubMed Web of Science ®Google Scholar
• Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367(9513):839–846. doi:10.1016/s0140-6736(06)68340-2
   PubMed Web of Science ®Google Scholar
• Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28(6):689–694. doi:10.1111/j.1525-1470.2011.01488.x
   PubMed Web of Science ®Google Scholar
• Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147(2):308–315. doi:10.1046/j.1365-2133.2002.04922.x
   PubMed Web of Science ®Google Scholar
• Murphy LA, Atherton DJ. Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr Dermatol. 2003;20(6):531–534. doi:10.1111/j.1525-1470.2003.20617.x
   Web of Science ®Google Scholar
• Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68(1):29–35. doi:10.1016/j.jaad.2012.07.001
   PubMed Web of Science ®Google Scholar
• Callen JP, Kulp-Shorten CL. 14 - Methotrexate. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy (Fourth Edition). Elsevier; 2021:156–168.e5.
   Google Scholar
• Methotrexate Tablets [Prescribing Information]. Huntsville: Qualitest Pharmaceuticals; 2016.
   Google Scholar
• Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156(2):346–351. doi:10.1111/j.1365-2133.2006.07686.x
   PubMed Web of Science ®Google Scholar
• Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353–359. doi:10.1016/j.jaci.2011.03.024
   PubMed Web of Science ®Google Scholar
• Roekevisch E, Schram ME, Leeflang MMG, et al. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data. J Allergy Clin Immunol. 2018;141(2):825–827.e10. doi:10.1016/j.jaci.2017.09.033
   PubMed Web of Science ®Google Scholar
• Gerbens LAA, Hamann SAS, Brouwer MWD, Roekevisch E, Leeflang MMG, Spuls PI. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol. 2018;178(6):1288–1296. doi:10.1111/bjd.16240
   PubMed Web of Science ®Google Scholar
• Goujon C, Viguier M, Staumont-Sallé D, et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a Phase III Randomized Noninferiority Trial. J Allergy Clin Immunol Pract. 2018;6(2):562–569.e3. doi:10.1016/j.jaip.2017.07.007
   PubMed Web of Science ®Google Scholar
• El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172(3):351–356. doi:10.1007/s00431-012-1893-3
   PubMed Web of Science ®Google Scholar
• Braue JA, Schadt CR, Zwerner JP. 16 - Mycophenolates. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy (Fourth Edition). Elsevier; 2021:178–186.e4.
   Google Scholar
• Cellcept® (Mycophenolate Mofetil) Capsules [Prescribing Information]. South San Francisco: Genentech, Inc; 2018.
   Google Scholar
• Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, De bruin-weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64(6):1074–1084. doi:10.1016/j.jaad.2010.04.027
   PubMed Web of Science ®Google Scholar
• Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 2001;137(7):870–873.
   Google Scholar
• Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143(2):385–391. doi:10.1046/j.1365-2133.2000.03667.x
   PubMed Web of Science ®Google Scholar
• Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat. 2020;31(8):810–814. doi:10.1080/09546634.2019.1642996
   PubMed Web of Science ®Google Scholar
• Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol. 2007;157(1):127–132. doi:10.1111/j.1365-2133.2007.07947.x
   PubMed Web of Science ®Google Scholar
• Grinich EE, Simpson EL. 31 - Additional biologic therapeutics: dupilumab, omalizumab, others. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy (Fourth Edition). Elsevier; 2021:339–348.e4.
   Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi:10.1056/NEJMoa1314768
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi:10.1056/NEJMoa1610020
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi:10.1016/s0140-6736(17)31191-1
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56. doi:10.1001/jamadermatol.2019.3336
   PubMed Web of Science ®Google Scholar
• Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85–96. doi:10.1111/bjd.18476
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals. Study to assess the long-term safety of dupilumab administered in participants ≥6 months to <18 years of age with atopic dermatitis (AD). NLM identifier: NCT02612454. Available from: https://clinicaltrials.gov/ct2/show/NCT02612454. Accessed February 12, 2021.
   Google Scholar
• Regeneron Pharmaceuticals. Study to investigate the efficacy and safety of dupilumab administered with Topical Corticosteroids (TCS) in participants ≥6 to <12 years with severe atopic dermatitis (AD). NLM identifier: NCT03345914. Available from: https://clinicaltrials.gov/ct2/show/NCT03345914?term=NCT03345914&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120–1135. doi:10.1111/bjd.18434
   PubMed Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473. doi:10.1111/bjd.17869
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals. Safety, pharmacokinetics and efficacy of dupilumab in patients ≥6 months to <6 years with moderate-to-severe atopic dermatitis (liberty AD PRESCHOOL) (Liberty AD). NLM identifier: NCT03346434. Available from: https://clinicaltrials.gov/ct2/show/NCT03346434?term=NCT03346434&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–141. doi:10.1016/j.jaci.2018.05.029
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2020. doi:10.1111/bjd.19574
   Web of Science ®Google Scholar
• Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2020. doi:10.1111/bjd.19573
   Web of Science ®Google Scholar
• LEO Pharma. Tralokinumab monotherapy for adolescent subjects with moderate to severe atopic dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). NLM identifier: NCT03526861. Available from: https://clinicaltrials.gov/ct2/show/NCT03526861?term=NCT03526861&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• LEO Pharma. Long-term extension Trial in subjects with atopic dermatitis who participated in previous tralokinumab trials - ECZTEND. NLM identifier: NCT03587805. Available from: https://clinicaltrials.gov/ct2/show/NCT03587805?term=NCT03587805&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a Phase 2b Randomized Clinical Trial. JAMA Dermatol. 2020;156(4):411–420. doi:10.1001/jamadermatol.2020.0079
   PubMed Web of Science ®Google Scholar
• Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled Phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863–871.e11. doi:10.1016/j.jaad.2018.01.017
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Long-term safety and efficacy Study of Lebrikizumab (LY3650150) in participants with moderate-to-severe atopic dermatitis. Available from: NLM identifier: NCT04392154. https://clinicaltrials.gov/ct2/show/NCT04392154?term=NCT04392154&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Eli Lilly and Company. Study to assess the safety and efficacy of lebrikizumab (LY3650150) in adolescent participants with moderate-to-severe atopic dermatitis (ADore). NLM identifier: NCT04250350. Available from: https://clinicaltrials.gov/ct2/show/NCT04250350?term=NCT04250350&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Eli Lilly and Company. Evaluation of the efficacy and safety of Lebrikizumab (LY3650150) in moderate to severe atopic dermatitis (ADvocate2). NLM identifier: NCT04178967. Available from: https://clinicaltrials.gov/ct2/show/NCT04178967?term=NCT04178967&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Eli Lilly and Company. Evaluation of the efficacy and safety of Lebrikizumab (LY3650150) in moderate to severe atopic dermatitis (ADvocate1). NLM identifier: NCT04146363. Available from: https://clinicaltrials.gov/ct2/show/NCT04146363?term=NCT04146363&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Eli Lilly and Company. Safety and efficacy of Lebrikizumab (LY3650150) in combination with topical corticosteroid in moderate-to-severe atopic dermatitis. (ADhere). NLM identifier: NCT04250337. Available from: https://clinicaltrials.gov/ct2/show/NCT04250337?term=NCT04250337&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835. doi:10.1056/NEJMoa1606490
   PubMed Web of Science ®Google Scholar
• Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, Phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121–1130.e7. doi:10.1016/j.jaci.2018.03.018
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182. doi:10.1016/j.jaci.2019.08.013
   PubMed Web of Science ®Google Scholar
• Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383(2):141–150. doi:10.1056/NEJMoa1917006
   PubMed Web of Science ®Google Scholar
• Galderma R&D. A pharmacokinetics and safety study of nemolizumab in adolescent subjects with atopic dermatitis (AD). NLM identifier: NCT03921411. Available from: https://clinicaltrials.gov/ct2/show/NCT03921411?term=NCT03921411&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Galderma R&D. Long-term safety and efficacy of nemolizumab with moderate-to-severe atopic dermatitis. NLM identifier: NCT03989206. Available from: https://clinicaltrials.gov/ct2/show/NCT03989206?term=NCT03989206&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Galderma R&D. Efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. NLM identifier: NCT03985943. Available from: https://clinicaltrials.gov/ct2/show/NCT03985943?term=NCT03985943&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Galderma R&D. Efficacy & safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. NLM identifier: NCT03989349. Available from: https://clinicaltrials.gov/ct2/show/NCT03989349?term=NCT03989349&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5):872–881.e6. doi:10.1016/j.jaad.2018.01.016
   PubMed Web of Science ®Google Scholar
• Weston G, Strober B. 18 - Phosphodiesterase-4 and Janus Kinase Inhibitors. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy (Fourth Edition). Elsevier; 2021:199–208.e3.
   Google Scholar
• Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.e9. doi:10.1016/j.jaad.2018.01.018
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi:10.1111/bjd.18898
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2020;156(12):1333–1343. doi:10.1001/jamadermatol.2020.3260
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. A Long-term Study of Baricitinib (LY3009104) with topical corticosteroids in adults with moderate to severe atopic dermatitis that are not controlled with cyclosporine or for those who cannot take oral cyclosporine because it is not medically advisable (BREEZE-AD4). NLM identifier: NCT03428100. Available from: https://clinicaltrials.gov/ct2/show/NCT03428100?term=NCT03428100&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Eli Lilly and Company. A Study of Baricitinib (LY3009104) in adult participants with moderate to severe atopic dermatitis (BREEZE-AD5). NLM identifier: NCT03435081. Available from: https://clinicaltrials.gov/ct2/show/NCT03435081?term=NCT03435081&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Eli Lilly and Company. A Study of Baricitinib (LY3009104) in children and adolescents with atopic dermatitis (BREEZE-AD-PEDS). NLM identifier: NCT03952559. Available from: https://clinicaltrials.gov/ct2/show/NCT03952559?term=NCT03952559&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Eli Lilly and Company. A Study of Long-term Baricitinib (LY3009104) therapy in atopic dermatitis. NLM identifier: NCT03334435. Available from: https://clinicaltrials.gov/ct2/show/NCT03334435?term=NCT03334435&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884. doi:10.1016/j.jaci.2019.11.025
   PubMed Web of Science ®Google Scholar
• AbbVie. Evaluation of upadacitinib in adolescent and adult patients with moderate to severe atopic dermatitis (Eczema) (Measure Up 1). NLM identifier: NCT03569293. Available from: https://clinicaltrials.gov/ct2/show/NCT03569293?term=NCT03569293&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• AbbVie. A study to evaluate upadacitinib in combination with topical corticosteroids in adolescent and adult participants with moderate to severe atopic dermatitis (AD Up). NLM identifier: NCT03568318. Available from: https://clinicaltrials.gov/ct2/show/NCT03568318?term=NCT03568318&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• AbbVie. A study to evaluate safety of upadacitinib in combination with topical corticosteroids in adolescent and adult participants with moderate to severe atopic dermatitis (Rising Up). NLM identifier: NCT03661138. Available from: https://clinicaltrials.gov/ct2/show/NCT03661138?term=NCT03661138&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• AbbVie. A study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis (Measure Up 2). NLM identifier: NCT03607422. Available from: https://clinicaltrials.gov/ct2/show/NCT03607422?term=NCT03607422&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• AbbVie. Open-label extension study of upadacitinib in adult participants with moderate to severe atopic dermatitis. NLM identifier: NCT04195698. Available from: https://clinicaltrials.gov/ct2/show/NCT04195698?term=NCT04195698&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• AbbVie. A study to evaluate the pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with severe atopic dermatitis. NLM identifier: NCT03646604. Available from: https://clinicaltrials.gov/ct2/show/NCT03646604?term=NCT03646604&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar
• Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a Phase 2 Randomized Clinical Trial. JAMA Dermatol. 2019;155(12):1371–1379. doi:10.1001/jamadermatol.2019.2855
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266. doi:10.1016/s0140-6736(20)30732-7
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2020;156(8):863–873. doi:10.1001/jamadermatol.2020.1406
   PubMed Web of Science ®Google Scholar
• Eichenfield L, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in adolescent patients with moderate-to-severe atopic dermatitis (AD): results From the Phase 3 JADE TEEN study [abstract]. J Allergy Clin Immunol. 2021;147(2):AB146. doi:10.1016/j.jaci.2020.12.529
   Web of Science ®Google Scholar
• Pfizer. Study to evaluate efficacy and safety of PF-04965842 with or without topical medications in subjects aged 12 years and older with moderate to severe atopic dermatitis (JADE EXTEND). NLM identifier: NCT03422822. Available from: https://clinicaltrials.gov/ct2/show/NCT03422822?term=NCT03422822&draw=2&rank=1. Accessed February 12, 2021.
   Google Scholar